The research gap that's leaving women with ADHD behind

Two research traditions, ADHD science and reproductive health, were built in parallel, around different populations, asking different questions. The result is a data architecture problem with measurable consequences for women with ADHD.

In 2021, Dorani et al. published one of the first clinical studies examining hormone-related mood disorders in women with ADHD. Their Dutch outpatient sample of 209 women found that 45.5% met criteria for PMDD and 57.6% reported a history of postpartum depression, rates far exceeding general population estimates of 3-8% and 10-15% respectively. Three years later, Broughton et al. extended this to a community sample of 715 women, finding a 3.19 to 4.17-fold increased risk of provisional PMDD among those with diagnosed or high-symptom ADHD.

These are striking numbers. What is more striking is what sits behind them: the two most methodologically rigorous studies tracking ADHD symptoms prospectively across the menstrual cycle have a combined sample of approximately 140 participants. A Swedish registry study tracking postpartum mental health outcomes drew on over 773,000 women and contained no ADHD measures whatsoever.

The datasets with the greatest statistical power to detect population-level patterns are precisely those blind to the neurodevelopmental variables that drive them.

Why the datasets don't connect

ADHD research has historically been built around male presentations. Reproductive health research was built around neurotypical women. Neither tradition was designed to ask questions that belonged to the other.

The practical consequence is systematic. ADHD datasets rarely incorporate prospective menstrual tracking, contraceptive adherence, or perinatal outcomes, relying instead on generic comorbidity fields that cannot capture luteal-phase symptom worsening or postpartum relapse patterns. Reproductive health registries and perinatal services, meanwhile, screen for depression and anxiety using tools like the Edinburgh Postnatal Depression Scale but do not include validated adult ADHD measures such as the Adult ADHD Self-Report Scale (ASRS).

The result is that neither system can see the population that falls between them, and both mistake the consequences of untreated ADHD for something else entirely.

What the biology explains

The mechanistic link between ADHD and reproductive transitions is well established at the neurobiological level, even if the clinical infrastructure has not caught up.

Estrogen modulates dopaminergic and serotonergic neurotransmission, the same pathways implicated in ADHD. During the late luteal phase of the menstrual cycle, estrogen levels drop sharply, reducing the dopaminergic buffer that supports executive function and emotional regulation. For individuals with ADHD, who already operate with reduced dopaminergic tone, this withdrawal produces measurable worsening of inattention, impulsivity, and emotional dysregulation, independent of any premenstrual mood disorder.

Lin et al. (2024) provided prospective confirmation of this pattern, tracking 58 women with PMDD across pre-ovulatory, mid-luteal, and late-luteal phases. Of those, 27.6% met criteria for comorbid ADHD, and executive dysfunction in this subgroup persisted beyond the late luteal phase, indicating a stable neurodevelopmental baseline with cyclical hormonal amplification, rather than purely a mood disorder.

This distinction matters clinically. Treating luteal-phase ADHD worsening as PMDD, without identifying the underlying neurodevelopmental condition, addresses the amplification while leaving the baseline entirely untreated.

The missing economic argument

Clinical evidence alone has rarely been sufficient to drive healthcare system change. What is also required is an economic case, and for the female-specific, hormone-sensitive dimension of ADHD, that case has not been made.

A German cost-benefit analysis (Bäuml et al., 2023) found that untreated ADHD was associated with an average per-capita lifetime earnings loss of approximately 92,000 euros, projecting a societal cost of 2.93 billion euros from a single childhood cohort alone. The authors concluded that reasonably effective intervention could justify considerable public investment.

No equivalent analysis exists for the reproductive health consequences of untreated ADHD in women. The five-fold elevated postpartum depression rate has not been costed. The unintended pregnancies associated with ADHD-related contraceptive nonadherence have not been modeled. The healthcare utilization generated by a diagnostic delay that spans the most reproductively significant decade of women's lives has not been calculated.

Without that fiscal evidence, commissioning bodies have no basis on which to fund integrated care, and the fragmented system persists by default.

What an integrated approach would look like

The measurement gap is addressable. A short tool combining the ASRS for baseline ADHD symptoms, prospective daily menstrual symptom diaries across at least two cycles, and items capturing contraceptive adherence and pregnancy intention would simultaneously enable ADHD and PMDD case-finding, distinguish stable neurodevelopmental impairment from cyclical mood exacerbation, and generate the population-level data needed to build an economic case for integrated services.

This is not a distant ambition. The component measures exist. The clinical settings for deployment, ADHD clinics, perinatal mental health services, reproductive health services, exist. What is missing is the institutional will to connect them.

Tracking your own patterns across your cycle using the Samphire app is one concrete step available now. Two cycles of daily symptom data gives you a personalized picture that belongs in clinical conversations, and contributes, in aggregate, to the evidence base this field still needs.

Frequently asked questions

Why don't ADHD services incorporate menstrual cycle tracking?

ADHD diagnostic and treatment frameworks were developed without reference to reproductive-stage variation, reflecting the male-dominated samples on which they were built. NICE NG87, the principal UK ADHD guideline, makes no reference to hormonal symptom variation or SRH coordination. This is beginning to be challenged in the research literature but has not yet translated into clinical practice.

What is the neurobiological mechanism connecting ADHD and the menstrual cycle?

Estrogen supports dopaminergic and serotonergic neurotransmission. During the late luteal phase, estrogen drops sharply, reducing the dopaminergic tone that supports executive function and emotional regulation. In individuals with ADHD, who already have reduced dopaminergic availability, this produces measurable worsening of core symptoms. This is distinct from PMDD, which involves a different neurobiological mechanism centered on sensitivity to allopregnanolone, a progesterone metabolite.

What is the difference between PMDD and premenstrual exacerbation of ADHD?

PMDD is defined in DSM-5 as a severe, cyclical mood disorder with at least five affective and somatic symptoms in the late luteal phase, confirmed prospectively across two cycles, with a symptom-free follicular interval. Premenstrual exacerbation (PME) of ADHD refers to worsening of chronically present ADHD symptoms premenstrually, without a symptom-free interval. The distinction matters for treatment: PMDD responds to SSRIs and hormonal interventions; PME of ADHD may require stimulant dose adjustment during the luteal phase.

What can I do if I think my ADHD and reproductive health are connected?

Begin with prospective symptom tracking across at least two full cycles, noting ADHD symptoms, mood, energy, and cycle phase daily. This gives you and your healthcare provider the longitudinal data needed to distinguish stable impairment from cyclical worsening. The Samphire app is designed to support exactly this kind of tracking.